Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab Ecteribulin (MORAb-202) in Metastatic NSCLC Adenocarcinoma
NCT05577715Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in lung adenocarcinoma (LUAD), sponsored by Bristol Myers Squibb. Primary endpoints: Objective Response Rate up to 12 months and Number of Participants With Drug-Related Adverse Events Leading to Discontinuation up to 12 months. Started Nov 2022; status: terminated.
02
Drugs
farletuzumab ecteribulin
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT05577715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577715.